Comparative incidence and health care costs of medically attended adverse effects among US medicaid HIV patients on atazanavir- or darunavir-based antiretroviral therapy

Johnston SS, Juday T, Esker S, Espindle D, Chu BC, Hebden T, Uy J

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
23538194

DOI
10.1016/j.jval.2012.10.021

Indexing Status
Subject indexing assigned by NLM

MeSH
Adolescent; Adult; Anti-HIV Agents /adverse effects /economics /therapeutic use; Atazanavir Sulfate; Darunavir; Exanthema /chemically induced /economics; Female; Gastrointestinal Diseases /chemically induced /economics; Glucose Metabolism Disorders /chemically induced /economics; HIV Infections /drug therapy /economics; Health Care Costs; Humans; Insurance Claim Review; Jaundice /chemically induced /economics; Lipid Metabolism Disorders /chemically induced /economics; Male; Medicaid /economics; Middle Aged; Oligopeptides /adverse effects /economics /therapeutic use; Pyridines /adverse effects /economics /therapeutic use; Retrospective Studies; Sulfonamides /adverse effects /economics /therapeutic use; United States; Young Adult

AccessionNumber
22013015860

Date bibliographic record published
13/05/2013